Today Stories

Now in its 11th year, MedTech Innovator continues to identify the best medical device, diagnostic and digital health startups developing innovative tools to improve patient care LOS ANGELES--(BUSINESS WIRE)--#innovator--MedTech Innovator, the world’s largest accelerator of medical technology companies, today announced the 2023 Accelerator Cohort. After a competitive selection process, 61 companies were chosen to participate in the MedTech Innovator’s flagship four-month MedTech Accelerator program. Featuring medical device, diagnostic, and digital health companies from around the globe, the 2023 Cohort members will get unparalleled visibility and access to leading medtech manufacturers, providers, investors, and other industry stakeholders. MedTech Innovator will additionally award $800,00…

Thermo Scientific Orbitrap Astral mass spectrometer combines high resolution and speed to accelerate the discovery of new proteins and advance precision medicine WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, one of the most significant advancements in mass spectrometry in 15 years. The new Astral analyzer combines fast throughput, high sensitivity and deep proteome coverage to allow researchers worldwide to uncover proteins that previously evaded detection and make breakthrough discoveries more efficiently than ever. Researchers can use this information to identify new clinical biomarkers, reveal diseases earlier and develop new interventions for eve…

Clinically validated lipid nanoparticle (LNP) delivery technology will further strengthen Bayer’s gene therapy portfolio / High potency ionizable lipid technology and LNP carriers allow for efficient, targeted, and transient delivery of gene editing RNA components to the liver  Berlin, June 5, 2023 – Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver. LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular deliver…

Chicago, IL (May 25, 2023) — Advanced Clinical, a privately held clinical research services organization committed to providing a better clinical experience across the drug development journey, is pleased to announce a biopharmaceutical industry-first collaboration with StuffThatWorks, the first data-driven community platform that uses crowdsourcing and AI to transform patient journeys and health metrics into actionable real world data in an effort to streamline research and bring clinical research closer to patients and caregivers. StuffThatWorks is home to 3M members world-wide who share their medical history and update on key condition and treatment parameters on an ongoing basis, in standard form across 750 conditions. Data shared by patients now amounts to 1.3M structured data points…

Company receives highest average rating across all 26 performance attributes out of 34 CROs included in survey and highest Net Promoter Score demonstrating likelihood to be recommended to colleagues DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced it has been rated the “Top CRO to Work With” by investigative sites worldwide in the 2023 WCG CenterWatch Global Site Relationship Benchmark Survey. Among the 34 CROs included in the survey, Parexel received the highest average rating across all 26 performance attributes evaluated. “Study start-up has significantly increased in complexity and the pressure on investigative sites has never…

Basel, Switzerland, May 31, 2023 – The Consumer Health Division of Bayer has launched a business unit focused on developing new Precision Health products across its range of everyday health categories. Bayer will prioritize developing products that enable people to take greater control of their own personal health through digital solutions that facilitate more informed choices based on personal insights and novel delivery mechanisms. The shift in the healthcare industry is clear, people need better self-care with the ability to predict, prevent and better manage their health. In fact, an analysis conducted for Bayer found over 80% of consumers globally already demand greater healthcare personalisation. Technology advancements have enabled a wave of new digital products such as diagnostics,…

New GMP facility to complete eXmoor’s transition from consultancy to one-stop global cell and gene therapy partner Bristol, UK, May 30, 2023 – eXmoor pharma, the end-to-end cell and gene therapy (CGT) manufacturing partner, today announced the close of a USD 35 million Series A financing round, from new investor Kineticos Ventures and existing investor MVM Partners. The funding will help launch eXmoor’s Cell and Gene Therapy Centre, a 65,000 sq ft GMP manufacturing facility, purpose-built to develop and manufacture autologous and allogeneic cell therapies, as well as viral vectors. In doing so, eXmoor will leverage nearly two decades of in-house facilities design, strategic CGT process development and translation consultancy experience to officially complete its expansion into a full-servi…

Life Edit will receive an upfront cash payment and is eligible to receive milestone payments of 250-335 million US dollars for each of seven development programmes, as well as tiered royalties on global net sales. Life Edit has the option to a global profit share on one programme. Novo Nordisk will make an equity investment in ElevateBio, Life Edit’s parent company, as part of ElevateBio’s 401 million US dollars Series D financing. Bagsværd, Denmark and Durham, NC, US, 24 May 2023 – Novo Nordisk and Life Edit Therapeutics, Inc., an ElevateBio company focused on next-generation gene editing technologies and therapeutics, today announced a research and development collaboration to discover and develop gene editing therapies against a select set of therapeutic targets. With a focus on advan…

Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines. Transformation of Grade II-listed Victorian waterworks on the River Thames in Hampton, London. Supplying many of the top biopharmaceutical companies in the world to dramatically enhance their ability to develop genetic medicines. Expansion follows recent acceptance of a Drug Master File and first investigational new drug application using doggybone DNA. Hampton, UK, 24 May 2023 – Touchlight, a company pioneering enzymatic DNA production, a critical material in many new genetic medicine treatments, has completed the redevelopment and expansion of its UK manufacturing facility, housed in a repurposed Victorian waterworks on the banks of the River Thames. The exp…

Global biopharmaceutical services provider Allucent has partnered with THREAD, an innovative decentralized clinical trial (DCT) and eCOA technology provider, to launch Allucent Patient Direct Trials, a DCT offering focused on small and mid-sized biotech companies. Allucent Patient Direct Trials provides small and mid-sized biotech companies with access to advanced technologies, operational experience, and regulatory expertise to design and execute more patient-focused trials and realize the efficiencies of a DCT approach. The announcement coincides with the 2023 World Orphan Drug Congress, where Allucent will lead a panel session on the value of decentralized study designs and protocol optimization, especially for rare disease therapeutic development.  CARY, N.C., May 23, 2023 – Global b…

Abbott's AVEIR™ DR i2i™ IDE study is the industry's first prospective study on the safety and performance of the world's first dual-chamber leadless pacemaker The study successfully met all three of its primary safety and performance endpoints Abbott's investigational AVEIR DR leadless pacemakers have been submitted for evaluation by the U.S. FDA NEW ORLEANS, May 20, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking results from the AVEIR™ dual-chamber (DR) i2i™ Investigational Device Exemption (IDE) study, a large-scale study to assess the world's first dual-chamber leadless pacemaker, showing that the leadless pacemaker met its three prespecified primary endpoints for safety and performance. The data further suggests that AVEIR DR could offer new benefits for people…

Tomorrow is #ClinicalTrialsDay 2023, a day dedicated to shining a spotlight on the clinical research community. Organised and promoted by ACRP since 2014, the day is celebrated on May 20th to recognise the day that James Lind started what is considered the first randomised clinical trial on May 20th, 1774. The day presents an opportunity for the community to pause in reflection, recognition, and admiration of all that has been accomplished thanks to clinical trials and the talented professionals driving them. Find out more about how you can get involved in #CTD2023: https://www.clinicaltrialsday.org/getinvolved

Healthcare Businesswomen’s Association Spotlights Jennifer Sozio and Caitlin Purinai for Biopharma Industry Impact MORRISVILLE, N.C., May 17, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced that Jennifer Sozio, SVP Clinical Operations, FSP360, and Caitlin Purinai, Senior Director, Human Resources Business Partner, have been recognized by the Healthcare Businesswomen’s Association (HBA) as admirable female leaders in the healthcare industry. “I am thrilled to see Jennifer Sozio and Caitlin Purinai recognized by the HBA for their outstanding performance and commitment to excellence,” said Michelle Keefe, CEO, Syneos Health. “Jennifer and Caitlin are role models for employees across the organization,…

Company Executives Honored for Notable Biopharmaceutical Industry Impact MORRISVILLE, N.C., May 16, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced PM360 has named Maria Fotiu, President, Sites and Patients, Syneos Health; Sayee Natarajan, CEO & Co-founder, RxDataScience (a Syneos Health company); and Greg Christie, Chief Product Officer, StudyKIK (a Syneos Health company), as recipients of its 9th Annual ELITE Awards. The PM360 ELITE Awards recognize individuals in 19 categories in the life sciences industry who exemplify the following traits: Exceptional Leaders, Innovators, Transformers, and Entrepreneurs (ELITE). Maria Fotiu is honored in the Strategists category for constantly leading her…

Accelerate@Babraham, the Babraham Research Campus’ programme supporting early-stage life science ventures, announces new cohort  Cambridge, UK, 16th May 2023: Babraham Research Campus Ltd, which is responsible for the development and management of the Babraham Research Campus is delighted to officially welcome six new ventures to Accelerate@Babraham 2023. Chosen via a rigorous selection process which culminated in short-listed companies being interviewed by representatives of the Babraham Research Campus executive team and all the programme’s strategic partners, the six winning ventures are: Aila Biotech – Co-Founders, James Dooley and Adrian Liston Aila Biotech is developing a unique biologic therapy with promising pre-clinical efficacy in neuroinflammation that has been validated in mult…

AmplifyBio is adding manufacturing services, starting with cell therapy and plasmids, to its growing capabilities to support the safe development of advanced therapies. WEST JEFFERSON, Ohio, May 15, 2023 (Newswire.com) - AmplifyBio, an emerging hub for the commercialization of advanced therapies, has announced the addition of cell therapy and plasmid manufacturing capabilities to its leading portfolio of preclinical CRO and drug characterization services. The GMP cell therapy and plasmid manufacturing labs, available in South San Francisco, are the latest step in AmplifyBio's broader strategy to build a development environment that de-risks the commercialization of next-generation therapeutics.  AmplifyBio recently acquired from PACT Pharma, Inc, a privately held biopharmaceutical company…

New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation The new programs build on a successful first year of the multi-million-dollar corporate initiative ABBOTT PARK, Ill., May 11, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on…

Collaboration will leverage Bicycle Therapeutic’s synthetic peptides for the discovery and development of multiple targeted radioconjugates of the company in oncology Advancing the use of bicycle peptides as a novel targeting approach in radiopharmaceuticals Bicycle Therapeutics to receive upfront payment of USD 45 million, and potential future development and commercial-based milestones, up to a total of USD 1.7 billion, plus tiered commercial royalties BERLIN & CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bayer and Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics by utilizing proprietary bicyclic peptides technology (Bicycle®), today announced that they have entered into a strategic collaboration agreeme…

– Acquisition of XinThera Provides Gilead with Precision Small Molecules Focused on PARP1 and MK2 Inhibitors – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation. Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. Both programs have the potential to address multiple indications, offering broad development opportunities alone and in…

Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation Net proceeds planned to be redeployed for debt repayment in accordance with Baxter’s stated capital allocation priorities Establishes a diversified, standalone contract development and manufacturing organization (CDMO) platform enhancing healthcare worldwide DEERFIELD Ill. and BOSTON and NEW YORK - 2023-05-08 Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced that it has signed a definitive agreement to divest its BioPharma Solutions (“BPS”) business to Advent International (“Advent”), one of the largest and most experienced global private equity investors, and Warburg…